Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

695 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 228
Recruiting: 123
Ph III recruiting: 18
Growth YoY: +39.5%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (82)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05152147	A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers(HERIZON-GEA-01)	active not recruiting	Phase 3	920	Jazz PharmaceuticalsINDUSTRY	33	Sep 24, 2026	clinicaltrials
NCT04248452	Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body	active not recruiting	Phase 3	314	ECOG-ACRIN Cancer Research Group